Exploring in silico drug design and pharmacokinetics study for identification of potent antidepressant agents

Document Type : Research Article

Authors

1 National Agency for Food and Drug Administration and Control (NAFDAC), Abuja Nigeria

2 bDepartment of Chemistry, Ahmadu Bello University Zaria, Nigeria

Abstract

In furtherance to our previous study, in silico drug design and pharmacokinetics study were employed on some arylpiperazine derivatives as inhibitors of serotonin transporter (SERT) for identification of potential antidepressant agents. A simulated molecular docking study carried out showed that the binding affinity between the receptor (PDB: 4m48) and the ligands range from -8.1 to -10.35kcal/mol with prominent hydrogen bonding and hydrophobic interactions. Some selected ligands displayed good binding affinity range from -9.55 to -10.35kcal/mol and remarkable biochemical interactions were revealed at the active site of the protein target compared to an FDA approved drug (Brexpiprazole) with a lower binding affinity (-9.5kcal/mol). More so, compound 15 shows an exceptional non-bonding interactions with five (5) hydrogen bonds to important amino acid residues (TYR124, ASP46, PHE319, SER421 and ASP475) at a shorter bond length (2.939Å) compared to Brexpiprazole with only one hydrogen bond to the amino acid residue (ASP401) at a longer bond length (3.754Å). Similarly, the predicted ADMET profiles revealed that all the selected compounds possessed good pharmacokinetics properties. Likewise, the computed drug-like properties of the selected compounds portends good pharmacological profiles/ bioavailability tendency as drug candidates. The BOILED-Egg graphics shows that all the selected compounds would be absorbed by the human gastrointestinal system and penetrate to the brain. Furthermore, the calculated physicochemical parameters of all the newly designed compounds having smaller molecular weights when compared with template compound with higher molecular weight satisfied the perquisites of drug-like compounds, an indication that the designed compounds would be orally bioavailable. Also, toxicity profiles of the designed compounds showed that none of the compounds portends carcinogenicity or skin sensitization toxicities. In consequence, all the selected and the designed compounds could be developed and optimized as potential antidepressant agents. However, further experimental studies and in vivo investigations are suggested to evaluate the mode of the actions and other pharmacological effects on these compounds.

Graphical Abstract

Exploring in silico drug design and pharmacokinetics study for identification of potent antidepressant agents

Keywords

Main Subjects


[1] S. B. Olasupo, A. Uzairu, G. S. Adamu, and S. Uba, “Computational Modeling and Pharmacokinetics/ADMET Study of Some Arylpiperazine Derivatives as Novel Antipsychotic Agents Targeting Depression,” Chem. Africa., 3 (2020) 1–10.
[2] N. Dessalew, “QSAR study on dual SET and NET reuptake inhibitors: an insight into the structural requirement for antidepressant activity,” J. Enzyme Inhib. Med. Chem.., 24 (2009) 262–271.
[3] S. B. Olasupo, A. Uzairu, G. A. Shallangwa, and S. Uba, “Profiling the antidepressant properties of Phenyl piperidine derivatives as inhibitors of serotonin transporter (SERT) via Cheminformatics Modeling, Molecular docking and ADMET predictions.,” Sci. African., 9 (2020) p. e00517.
[4] M. Gabrielsen, A. W. Ravna, K. Kristiansen, and I. Sylte, “Substrate binding and translocation of the serotonin transporter studied by docking and molecular dynamics simulations,” J. Mol. Model., 18 (2012) 1073–1085.
[5] I. C. Muszynski, L. Scapozza, K. Kovar, and G. Folkers, “Quantitative structure‐activity relationships of phenyltropanes as inhibitors of three monoamine transporters: Classical and CoMFA studies,” Quant. Struct. Relationships., 18 (1999) 342–353.
[6] S. Bhat, A. H. Newman, and M. Freissmuth, “How to rescue misfolded SERT, DAT and NET: targeting conformational intermediates with atypical inhibitors and partial releasers,” Biochem. Soc. Trans., 47 (2019) 861–874.
[7] Y. Yang et al., “Computational analysis of structure-based interactions for novel H1-antihistamines,” Int. J. Mol. Sci., 17 (2016) 129.
[8] J. Wang et al., “Profiling the interaction mechanism of indole-based derivatives targeting the HIV-1 gp120 receptor,” RSC Adv., 5 (2015) 78278–78298.
[9] S. B. Olasupo, A. Uzairu, G. Shallangwa, and S. Uba, “QSAR analysis and molecular docking simulation of norepinephrine transporter (NET) inhibitors as anti-psychotic therapeutic agents,” Heliyon., 5 (2019) e02640.
[10] A. Penmatsa, K. H. Wang, and E. Gouaux, “X-ray structure of dopamine transporter elucidates antidepressant mechanism,” Nature., 503 (2013) 85.
[11] P. T. Mpiana et al., “Identification of potential inhibitors of SARS-CoV-2 main protease from Aloe vera compounds: a molecular docking study,” Chem. Phys. Lett., 754 (2020) 137751
[12] S. S. ul Hassan, W.-D. Zhang, H. Jin, S. H. Basha, and S. V. S. S. Priya, “In-silico anti-inflammatory potential of guaiane dimers from Xylopia vielana targeting COX-2,” J. Biomol. Struct. Dyn., 1 (2020) 1–15.
[13] A. Daina, O. Michielin, and V. Zoete, “SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules,” Sci. Rep., 7 (2017) 42717.
[14] D. E. V Pires, T. L. Blundell, and D. B. Ascher, “pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures,” J. Med. Chem., 58 (2015) 4066–4072.
[15] M. Cheminformatics, “Calculation of molecular properties and bioactivity score,” Comput. software]. Retrieved from http//www. molinspiration. com/cgi-bin/properties, (2018).
[16] F. Cheng et al., “Correction to ‘admetSAR: A Comprehensive Source and Free Tool for Assessment of Chemical ADMET Properties,’” J. Chem. Inf. Model., 59 (2019) 4959.
[17] C. A. Lipinski, “Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions,” Adv. Drug Deliv. Rev., 101 (2016) 34–41.
[18] S. B. Olasupo, A. Uzairu, G. A. Shallangwa, and S. Uba, “Chemoinformatic studies on some inhibitors of dopamine transporter and the receptor targeting schizophrenia for developing novel antipsychotic agents,” Heliyon, 6 (2020) e04464.
[19] N. Brooijmans, “Docking methods, ligand design, and validating data sets in the structural genomic era,” Struct. Bioinformatics. JGaPE Bourne, Ed. John Wiley Sons, ( 2009)
[20] S. Roy, L. R. Samant, and A. Chowdhary, “In silico pharmacokinetics analysis and ADMET of phytochemicals of Datura metel Linn. and Cynodon dactylon Linn,” J. Chem. Pharm. Res., 7 (2015) 385–388.
[21] A. Daina and V. Zoete, “A boiled‐egg to predict gastrointestinal absorption and brain penetration of small molecules,” ChemMedChem., 11 (2016) 1117–1121.
[22] S. Babatunde, O. Adamu, U. Gideon, and S. Sani, “QSAR modeling , molecular docking and ADMET / pharmacokinetic studies : a chemometrics approach to search for novel inhibitors of norepinephrine transporter as potent antipsychotic drugs,” J. Iran. Chem. Soc., 17 (2020) 1953–1966.
[23] S. E. Adeniji, D. E. Arthur, M. Abdullahi, and A. Haruna, “Quantitative structure–activity relationship model, molecular docking simulation and computational design of some novel compounds against DNA gyrase receptor,” Chem. Africa, 3 (2020) 391–408.